| Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease |
| Received:August 22, 2023 Revised:October 11, 2023 Click here to download the full text |
| Citation of this paper:CHENG Hui,PENG Jie-cheng,WU Wan-shi,JIANG Qing.Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease[J].Chinese Journal of Clinical Medicine,2023,30(6):1010-1014 |
| Hits: 405 |
| Download times: 175 |
| Author Name | Affiliation | E-mail | | CHENG Hui | Department of Cardiovascular Medicine, Anqing First People's Hospital Affiliated to Anhui Medical University, Anqing 246000, Anhui, China | | | PENG Jie-cheng | Department of Cardiovascular Medicine, Anqing First People's Hospital Affiliated to Anhui Medical University, Anqing 246000, Anhui, China | pengjiec@163.com | | WU Wan-shi | Department of Cardiovascular Medicine, Anqing First People's Hospital Affiliated to Anhui Medical University, Anqing 246000, Anhui, China | | | JIANG Qing | Department of Cardiovascular Medicine, Anqing First People's Hospital Affiliated to Anhui Medical University, Anqing 246000, Anhui, China | |
|
| Abstract:Objective To explore the safety and efficacy of drug-coated balloon (DCB) in the treatment of de novo coronary artery disease. Methods A total of 85 patients with de novo coronary artery disease undergoing interventional therapy in Anqing First People's Hospital Affiliated to Anhui Medical University from February 2021 to June 2022 were retrospectively included, and were divided into drug-eluting stent (DES) group (n=45) and DCB group (n=40) according to different interventional therapies. The minimal lumen diameter (MLD) and the degree of lumen stenosis before surgery, immediately after surgery and at 6 months after surgery, immediate success rate of surgery and incidence of intraoperative complications, late lumen loss (LLL) at 6 months after surgery, incidence of major adverse cardiovascular event (MACE) within 6 months after surgery were compared between the two groups. Results Immediately and at 6 months after surgery, MLD in DCB group was significantly shorter than that in DES group (P<0.001). Immediately after surgery, lumen stenosis in DCB group was significantly severer than that in DES group (P<0.001), but there was no significant difference between the two groups at 6 months after surgery. There was no significant difference in immediate success rate of surgery between DCB group and DES group (95.00% vs 97.78%). There was no significant difference in incidence of intraoperative complications between the two groups. At 6 months after surgery, incidences of LLL and MACE in DCB group were significantly lower than those in DES group (P<0.05). Conclusions DCB interventional therapy has high immediate success rate of surgery for de novo coronary artery disease, which can significantly improve arterial vascular stenosis, with good safety. |
| keywords:de novo coronary artery disease drug-coated balloon drug-eluting stent major adverse cardiovascular event |
| HTML View Full Text View/Add Comment Download reader |
|
|
|